)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
IDEAYA Biosciences
IDEAYA Biosciences (IDYA) investor relations material
IDEAYA Biosciences Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary9 Mar, 2026
Vision and strategy
Aims to build a leading precision medicine oncology company with a focus on first- and best-in-class programs using predictive biomarkers and AI-driven drug discovery.
Research targets neoadjuvant/adjuvant indications, 1L metastatic disease, rational combinations, and tumor heterogeneity.
Drug discovery platform
Six internally discovered clinical-stage molecules address challenging targets like helicases, polymerases, and glycohydrolases.
Core capabilities include CRISPR-based discovery, chemigenomics, AI-driven drug design, and novel selectivity profiles.
Darovasertib for uveal melanoma (UM)
Targets PKC pathway, driven by GNAQ/11 mutations in >95% of UM patients, with potential to be first targeted therapy for all UM stages.
Combination with crizotinib aims to improve survival in metastatic UM, regardless of HLA status.
Phase 2/3 trials show median PFS of 7.0 months and OS of 21.1 months, outperforming historical data.
Neoadjuvant trials demonstrate robust tumor shrinkage, eye preservation, and visual improvement.
OptimUM-02 PFS event threshold for AA filing
IDE161 synergy mechanism with TOP1 ADCs
IDE397 and IDE892 combo rationale in NSCLC
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from IDEAYA Biosciences
- Darovasertib phase III readout nears, with strong efficacy and broad pipeline progress.IDYA
Status update23 Feb 2026 - Major data readout for darovasertib/crizotinib in uveal melanoma expected by end of March.IDYACiti’s 2026 Virtual Oncology Leadership Summit18 Feb 2026
- Strong clinical progress and improved financials, with topline trial results due March 2026.IDYAQ4 202517 Feb 2026
- 39% response and 94% disease control achieved in MTAP-deleted NSCLC and urothelial cancer.IDYAStudy Update3 Feb 2026
- Strong clinical progress and pipeline expansion position the company for significant growth.IDYAGoldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026
- Darovosertib shows high efficacy in uveal melanoma, with key phase II and regulatory updates ahead.IDYAJefferies 2024 Global Healthcare Conference31 Jan 2026
- Darovasertib and MTAP-targeted therapies advance, with pivotal data and regulatory milestones ahead.IDYAMorgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026
- Darovasertib achieved 61% eye preservation and strong tumor shrinkage in uveal melanoma trials.IDYAStudy Update20 Jan 2026
- Strong clinical and commercial momentum positions for a late 2026 launch in oncology.IDYAJefferies London Healthcare Conference 202413 Jan 2026
Next IDEAYA Biosciences earnings date
Q1 20266 May, 2026
IDEAYA Biosciences
Next IDEAYA Biosciences earnings date
Q1 20266 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage